A Phase 3 interventional study of Sirolimus in Complication of Renal Dialysis, End Stage Renal Disease and End Stage Kidney Disease, sponsored by Vascular Therapies, Inc.. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Vascular Therapies, Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sirolimus in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Sirolimus · Kidney Failure, Chronic.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 12th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies testing sirolimus in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 12 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 8 most frequent:
Vascular Therapies, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Vascular Therapies, Inc. has 2 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing sirolimus in Kidney Failure, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
This is a Phase 3, multicenter, randomized, single-blind, controlled, study designed to evaluate the efficacy and safety of the use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects who are on hemodialysis and are undergoing surgical creation of an AV fistula in comparison to subjects who do not receive the implant.
Subjects of either gender, who are at least 65 years of age, undergoing hemodialysis, and require a new single stage radiocephalic end to side fistula will be eligible to participate in this study. Subjects who meet eligibility criteria and undergo successful AV fistula creation will be eligible for enrollment. The study plans to enroll approximately 120 subjects, randomized in a 1:1 ratio. Enrolled subjects will be followed for a period of one year from the time of their index surgical procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the treatment arm will undergo AV fistula surgery and will receive the Sirolimus eluting Collagen Implant (SeCI).
Drug: Sirolimus
Subjects randomized to the control arm will undergo AV fistula surgery alone and will not receive an implant.
SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
Also known as: Sirolimus-eluting Collagen Implant, SeCI, Sirogen
Percentage of Participants With Clinical Fistula Maturation (FM)
Clinical Fistula Maturation (FM) is defined as a fistula that can be cannulated with 2-needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of 300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30 day period that commences no later than 180 days after randomization. FM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The KM proportions (and associated 95% CIs) for FM for the two groups will be evaluated on day 210.
Time frame: 6 Months
Fistula Suitability for Dialysis at 12 Months (FSD12)
Fistula Suitability for Dialysis at 12 months (FSD12) defined as a fistula that can be used for dialysis using 2 needles for at least 75% of the dialysis sessions performed during a 30 day period that commences on day 330.
Time frame: 1 year
Percentage of Participants With Secondary Patency at 12 Months
Secondary Patency (SP) defined as the interval from the time of randomization until access abandonment. SP will be summarized as the cumulative proportion of abandoned AVF by plotting the (inverted SP) Kaplan-Meier (KM) curves for each treatment group and estimating the KM proportions (and associated 95% CIs) of AVF that have maintained SP by day 360 or end of study visit (whichever is later).
Time frame: 12 Months
Percentage of Participants With First Dialysis (TTFD) at 12 Months
Time To First Dialysis (TTFD) defined as the interval from the time of randomization to the first of three consecutive dialysis sessions using 2 needles with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min). TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for each group (treatment and controls) and estimating the KM proportions (and associated 95% CIs) achieving first dialysis by day 360. TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The TTFD proportions (and associated 95% CIs) for TTFD for the two groups will be evaluated on day 360.
Time frame: 12 Months
Percentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months
Mature Fistula with Preserved Function at 12 Months (MFPF) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles for at least 75% of the for the dialysis sessions performed during a 30-day period that commences on day 330 (FSD12). MFPF will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The MFPF proportions (and associated 95% CIs) for MFPF for the two groups will be evaluated on day 360.
Time frame: 12 Months
Percentage of Participants With Durable Fistula Maturation (DFM) at 12 Months
Durable Fistula Maturation (DFM) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles with a mean Qb of ≥300 mL/min for the dialysis sessions performed during a 30-day period that commences on day 330. DFM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The DFM proportions (and associated 95% CIs) for DFM for the two groups will be evaluated on day 360.
Time frame: 12 Months
Cumulative Fistula Use (CFU)
Cumulative Fistula Use (CFU) defined as the number of dialysis sessions performed using the study fistula with 2 needles and a mean Qb of ≥300 mL/min. CFU is calculated from the time of fistula creation to the end of study period or upon reaching an intercurrent event (Fistula abandonment, Death, Transfer to PD or transplant) or is lost to follow up. CFU was calculated for each participant and then averaged together.
Time frame: 12 Months
Cumulative Catheter Exposure (CCE)
Cumulative Catheter Exposure (CCE) is defined as the number of days a hemodialysis central venous catheter (CVC) is in situ and the duration of CVC exposure is calculated from the day of fistula creation (i.e., day of randomization) to the end of study period or upon reaching an intercurrent event. CFU was calculated for each participant and then averaged together.
Time frame: 12 Months
| Milestone | Treatment Arm | Control Arm |
|---|---|---|
| Started | 68 | 67 |
| Completed | 59 | 61 |
| Not completed | 9 | 6 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 7 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Clinical Fistula Maturation (FM) is defined as a fistula that can be cannulated with 2-needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of 300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30 day period that commences no later than 180 days after randomization. FM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The KM proportions (and associated 95% CIs) for FM for the two groups will be evaluated on day 210.
| Percentage of participants | Treatment Arm | Control Arm |
|---|---|---|
| Percentage of Participants With Clinical Fistula Maturation (FM) | 69.8 (55.9 to 82.7) | 65.9 (53 to 78.4) |
Fistula Suitability for Dialysis at 12 months (FSD12) defined as a fistula that can be used for dialysis using 2 needles for at least 75% of the dialysis sessions performed during a 30 day period that commences on day 330.
| Participants | Treatment Arm | Control Arm |
|---|---|---|
| Fistula Suitability for Dialysis at 12 Months (FSD12) | 35 | 40 |
Secondary Patency (SP) defined as the interval from the time of randomization until access abandonment. SP will be summarized as the cumulative proportion of abandoned AVF by plotting the (inverted SP) Kaplan-Meier (KM) curves for each treatment group and estimating the KM proportions (and associated 95% CIs) of AVF that have maintained SP by day 360 or end of study visit (whichever is later).
| Percentage of participants | Treatment Arm | Control Arm |
|---|---|---|
| Percentage of Participants With Secondary Patency at 12 Months | 67.3 (54.3 to 77.3) | 64.8 (44.1 to 79.5) |
Time To First Dialysis (TTFD) defined as the interval from the time of randomization to the first of three consecutive dialysis sessions using 2 needles with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min). TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for each group (treatment and controls) and estimating the KM proportions (and associated 95% CIs) achieving first dialysis by day 360. TTFD will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The TTFD proportions (and associated 95% CIs) for TTFD for the two groups will be evaluated on day 360.
| Percentage of participants | Treatment Arm | Control Arm |
|---|---|---|
| Percentage of Participants With First Dialysis (TTFD) at 12 Months | 85.7 (72.5 to 94.7) | 82.2 (70.1 to 91.6) |
Mature Fistula with Preserved Function at 12 Months (MFPF) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min (unless the prescribed Qb is \<300 mL/min) performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles for at least 75% of the for the dialysis sessions performed during a 30-day period that commences on day 330 (FSD12). MFPF will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The MFPF proportions (and associated 95% CIs) for MFPF for the two groups will be evaluated on day 360.
| Percentage of participants | Treatment Arm | Control Arm |
|---|---|---|
| Percentage of Participants With Mature Fistula With Preserved Function (MFPF) at 12 Months | 60.7 (46.8 to 75) | 60.6 (47.6 to 73.8) |
Durable Fistula Maturation (DFM) defined as a fistula that can be cannulated with 2 needles for at least 75% of the dialysis sessions, including 3 consecutive sessions with a mean Qb of ≥300 mL/min performed during any continuous 30-day period that commences no later than 180 days after randomization (i.e., fistula achieves FM) AND can be used for dialysis using 2-needles with a mean Qb of ≥300 mL/min for the dialysis sessions performed during a 30-day period that commences on day 330. DFM will be summarized by plotting the (inverted) Kaplan-Meier (KM) curves for the treatment and control groups. The DFM proportions (and associated 95% CIs) for DFM for the two groups will be evaluated on day 360.
| Percentage of participants | Treatment Arm | Control Arm |
|---|---|---|
| Percentage of Participants With Durable Fistula Maturation (DFM) at 12 Months | 52.3 (38.7 to 67.3) | 41.7 (29.9 to 55.9) |
Cumulative Fistula Use (CFU) defined as the number of dialysis sessions performed using the study fistula with 2 needles and a mean Qb of ≥300 mL/min. CFU is calculated from the time of fistula creation to the end of study period or upon reaching an intercurrent event (Fistula abandonment, Death, Transfer to PD or transplant) or is lost to follow up. CFU was calculated for each participant and then averaged together.
| Sessions per 1,000 dialysis session days | Treatment Arm | Control Arm |
|---|---|---|
| Cumulative Fistula Use (CFU) | 582 ± 212 | 496 ± 240 |
Cumulative Catheter Exposure (CCE) is defined as the number of days a hemodialysis central venous catheter (CVC) is in situ and the duration of CVC exposure is calculated from the day of fistula creation (i.e., day of randomization) to the end of study period or upon reaching an intercurrent event. CFU was calculated for each participant and then averaged together.
| Sessions per 1,000 dialysis session days | Treatment Arm | Control Arm |
|---|---|---|
| Cumulative Catheter Exposure (CCE) | 702 ± 328 | 677 ± 317 |
Collected over From enrollment until end of follow-up, up to 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Arm | 7/68 (10.3%) | 29/68 (42.6%) | 56/68 (82.4%) |
| Control Arm | 4/67 (6%) | 26/67 (38.8%) | 62/67 (92.5%) |
| Event | Treatment Arm | Control Arm |
|---|---|---|
| HypervolaemiaMetabolism and nutrition disorders | 2/68 | 5/67 |
| Coronary artery diseaseCardiac disorders | 3/68 | 1/67 |
| Atrial fibrillationCardiac disorders | 0/68 | 2/67 |
| Cardiac failure congestiveCardiac disorders | 2/68 | 2/67 |
| DeathGeneral disorders | 0/68 | 2/67 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/68 | 2/67 |
| Renal transplantSurgical and medical procedures | 1/68 | 2/67 |
| HypertensionVascular disorders | 1/68 | 2/67 |
| HypotensionVascular disorders | 1/68 | 2/67 |
| AnaemiaBlood and lymphatic system disorders | 2/68 | 1/67 |
| Event | Treatment Arm | Control Arm |
|---|---|---|
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 43/68 | 48/67 |
| Vascular access site extravasationInjury, poisoning and procedural complications | 23/68 | 26/67 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 13/68 | 9/67 |
| Arteriovenous fistula maturation failureInjury, poisoning and procedural complications | 8/68 | 9/67 |
| Vascular access complicationInjury, poisoning and procedural complications | 8/68 | 9/67 |
| Device related thrombosisGeneral disorders | 1/68 | 4/67 |
| Arteriovenous fistula site haematomaInjury, poisoning and procedural complications | 2/68 | 4/67 |
| Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications | 0/68 | 3/67 |
| Vascular access site complicationInjury, poisoning and procedural complications | 0/68 | 3/67 |
| Arteriovenous fistula occlusionInjury, poisoning and procedural complications | 1/68 | 2/67 |
1 subject randomized to the control arm was removed from analysis due to a major protocol deviation, i.e., subject was not on hemodialysis at the time of enrollment.
| Age, Continuous(Years) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| Mean | 72.6 ± 6.2 | 73.0 ± 6.4 | 72.8 ± 6.3 |
| Sex: Female, Male(Participants) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| Female | 20 | 24 | 44 |
| Male | 48 | 43 | 91 |
| Race (NIH/OMB)(Participants) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 19 | 12 | 31 |
| White | 41 | 49 | 90 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 17 | 18 | 35 |
| Not Hispanic or Latino | 49 | 46 | 95 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Region of Enrollment(Participants) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| United States | 50 | 49 | 99 |
| United Kingdom | 18 | 18 | 36 |
| Duration of hemodialysis(Months) | Treatment Arm | Control Arm | Total |
|---|---|---|---|
| Mean | 5.29 ± 3.59 | 4.78 ± 3.2 | 5.04 ± 3.39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data (IPD) collected in this study will not be shared.
Ran from Aug 2022 to primary completion in Mar 2025, 30 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 30 months is close to that.
Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Vascular Therapies, Inc.